BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16751787)

  • 1. Optimizing the use of cyclosporin in allogeneic stem cell transplantation.
    Duncan N; Craddock C
    Bone Marrow Transplant; 2006 Aug; 38(3):169-74. PubMed ID: 16751787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cyclosporine A at a high-peak concentration of twice-daily infusion and oral administration in allogeneic haematopoietic stem cell transplantation.
    Inoue Y; Saito T; Ogawa K; Nishio Y; Kosugi S; Suzuki Y; Shibuya Y; Kato M; Takahashi M; Miura I
    J Clin Pharm Ther; 2011 Aug; 36(4):518-24. PubMed ID: 21105879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
    Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
    Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients.
    Hendriks MP; Blijlevens NM; Schattenberg AV; Burger DM; Donnelly JP
    Bone Marrow Transplant; 2006 Oct; 38(7):521-5. PubMed ID: 16981000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
    Schrauder A; Saleh S; Sykora KW; Hoy H; Welte K; Boos J; Hempel G; Grigull L
    Pediatr Transplant; 2009 Jun; 13(4):444-50. PubMed ID: 18482216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
    Bleyzac N
    Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible cortical blindness and convulsions with cyclosporin A toxicity in a patient undergoing allogeneic peripheral stem cell transplantation.
    Madan B; Schey SA
    Bone Marrow Transplant; 1997 Nov; 20(9):793-5. PubMed ID: 9384485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients.
    Jin M; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Bone Marrow Transplant; 2008 Oct; 42(7):455-9. PubMed ID: 18622423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients.
    Leather H; Boyette RM; Tian L; Wingard JR
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):325-34. PubMed ID: 16503502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
    Izumi N; Furukawa T; Sato N; Okazuka K; Tsukada N; Abe T; Yano T; Kurasaki T; Masuko M; Toba K; Takahashi M; Aizawa Y
    Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
    Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
    Sibbald C; Seto W; Taylor T; Saunders EF; Doyle J; Dupuis LL
    Ther Drug Monit; 2008 Aug; 30(4):434-8. PubMed ID: 18641547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants.
    Hoyt R; Ritchie DS; Roberts AW; Macgregor L; Curtis DJ; Szer J; Grigg AP
    Bone Marrow Transplant; 2008 Apr; 41(7):651-8. PubMed ID: 18176619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention and treatment of acute GvHD.
    Messina C; Faraci M; de Fazio V; Dini G; Calò MP; Calore E;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S65-70. PubMed ID: 18545247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular findings after allogeneic hematopoietic stem cell transplantation.
    Tabbara KF; Al-Ghamdi A; Al-Mohareb F; Ayas M; Chaudhri N; Al-Sharif F; Al-Zahrani H; Mohammed SY; Nassar A; Aljurf M
    Ophthalmology; 2009 Sep; 116(9):1624-9. PubMed ID: 19729097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.